healthcare

DNA

Can Immunomedics Double?

Immunomedics Inc. (NASDAQ: IMMU) may be poised to make big moves going forward in 2015, according to a key analyst. In fact, Wells Fargo sees this biotech company potentially doubling. ...
Read Full Story »
health care

Will Schizophrenia and Bipolar Patients Trust Generic Abilify?

The trend towards generic drugs is nothing new. It does not matter if a drug has billions of dollars in annual sales or not, when they go off patent generics ...
Read Full Story »
Prescription drugs

Despite Currencies, Merck Delivers on Earnings

Merck & Co. Inc. (NYSE: MRK) has managed to beat its first-quarter earnings expectations, and handily at that. The drug giant and Dow Jones Industrial Average component reported earnings of $0.85 per ...
Read Full Story »
Pfizer logo

Pfizer Dodges a Bullet on Earnings

Pfizer Inc. (NYSE: PFE) has reported first-quarter earnings of $0.51 per share, versus the $0.49 expected from Thomson Reuters. Revenues were $10.86 billion, compared to $10.76 billion expected. For 2015, ...
Read Full Story »
generic drugs

Key Analyst Sees Nearly 30% Upside in Ironwood

With the health care sector still on fire this year, Merrill Lynch brings another company to the forefront that it considers a buy. Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) is viewed ...
Read Full Story »
upgrade

GW Pharma Gets Big Analyst Upgrade Into Cannabinoid FDA Orphan Drug Designation

GW Pharmaceuticals PLC (NASDAQ: GWPH) was recently listed as the top medical marijuana stock for National Weed Day, but other things are going on here besides weird holidays. GW recently ...
Read Full Story »
Rite Aid

3 Top Stocks to Buy That Delivered Great Earnings

While often the top firms on Wall Street take a shot and advise clients to buy stocks in front of earnings, that only works when they actually beat earnings and ...
Read Full Story »
145922793

Can La Jolla Pharma Shares Really Double?

Health care is still going strong in April, and biotech and emerging pharmaceutical stocks still have huge gains so far in 2015. La Jolla Pharmaceutical Co. (NASDAQ: LJPC) has seen ...
Read Full Story »
Prescription drugs

Why Teva Really Wants to Acquire Mylan

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has just approached Mylan N.V. (NASDAQ: MYL) with a public takeover bid valued at $82 per share in cash and stock. The offering would consist ...
Read Full Story »
research

BioCryst Upgrade Almost Looks Misunderstood

The most recent analyst call by Merrill Lynch for BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) may be very misunderstood for what it is. The brokerage firm upgraded BioCryst to Neutral and ...
Read Full Story »
DNA

Genetic Technologies Drives Ahead in the Fight Against Cancer

Genetic Technologies Limited (NASDAQ: GENE) has been making large strides in the area of women’s health recently with the opening of more centers that utilize the BREVAGenplus. Ultimately this will ...
Read Full Story »
knees

Is Ampio at Risk of Imploding?

Companies in the biotech and pharmaceuticals field are generally riskier than other companies because a single failed study could make or break the company, similar to what happened with Ampio ...
Read Full Story »
Pills

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

One thing investors look for in an aging bull market, especially one trading near all-time highs, is rising earnings. That is the only way to justify multiples that creep up ...
Read Full Story »
biotech

5 Big Biotechs Not Keeping Up at All With Hot Biotech Sector in 2015

The health care sector and biotech in particular have been on fire so far in 2015, but some biotech stocks in the group just are not carrying their weight. The ...
Read Full Story »
biotech

Akebia Hits New Low After Pricing Secondary Offering

Akebia Therapeutics Inc. (NASDAQ: AKBA) announced the pricing for its secondary offering Thursday evening. A total of 7.27 million shares of common stock were registered for the offering at a ...
Read Full Story »